Grifols (GIFLF) Depreciation & Amortization (CF) (2010 - 2020)
Grifols' (GIFLF) quarterly Depreciation & Amortization (CF) came in at $85.6 million in Q1 2020, up 1.15% on a YoY basis from $84.7 million in Q2 2019, and down 65.48% quarter-over-quarter from $248.1 million in Q4 2019.
Analysis
Grifols (GIFLF) Depreciation & Amortization (CF) (2010 - 2020) Analysis & Trends
Grifols (GIFLF) has reported Depreciation & Amortization (CF) for 11 consecutive years, with $85.6 million the latest figure, recorded in Q1 2020.
- For the quarter ending Q1 2020, Depreciation & Amortization (CF) rose 1.15% year-over-year to $85.6 million; the trailing twelve-month figure through Dec 2025 stood at $0.0 (changed 0.0% YoY), and the FY2025 full-year result was $508.4 million, up 8.63% from the prior year.
- Depreciation & Amortization (CF) eased to $85.6 million in Q1 2020 per GIFLF's latest filing, from $248.1 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $1.4 billion in Q4 2016 and bottomed at -$1.1 billion in Q2 2016.
- Historically, Depreciation & Amortization (CF) has averaged $198.2 million across 5 years, with a median of $84.7 million in 2019.
- The widest YoY moves for Depreciation & Amortization (CF): up 2345.14% in 2016, down 2283.99% in 2016.
- Over 5 years, Depreciation & Amortization (CF) stood at $1.4 billion in 2016, then sank by 86.64% to $186.5 million in 2017, then grew by 1.84% to $189.9 million in 2018, then jumped by 30.64% to $248.1 million in 2019, then sank by 65.48% to $85.6 million in 2020.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $85.6 million, $248.1 million, and $84.7 million for Q1 2020, Q4 2019, and Q1 2019 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 1.11 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 56.50 Mn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 123.70 Mn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 236.10 Mn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 600,000.00 |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | 85.64 Mn |
| Dec 31, 2019 | 248.08 Mn |
| Mar 31, 2019 | 84.66 Mn |
| Dec 31, 2018 | 189.89 Mn |
| Jun 30, 2018 | 65.73 Mn |
| Mar 31, 2018 | 64.97 Mn |
| Dec 31, 2017 | 186.46 Mn |
| Jun 30, 2017 | 58.53 Mn |
| Mar 31, 2017 | 56.80 Mn |
| Dec 31, 2016 | 1.40 Bn |
| Sep 30, 2016 | 55.63 Mn |
| Jun 30, 2016 | -1.12 Bn |
| Mar 31, 2016 | 1.21 Bn |
| Dec 31, 2015 | 1.18 Bn |
| Sep 30, 2015 | 54.14 Mn |
| Jun 30, 2015 | 51.35 Mn |
| Mar 31, 2015 | 49.33 Mn |
| Dec 31, 2014 | 1.05 Bn |
| Sep 30, 2014 | 183.76 Mn |
| Jun 30, 2014 | -63.47 Mn |